{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics Hits New 52-Week High of $21.71, Soars 186.87%
Arcutis Biotherapeutics, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. The company reported substantial growth in net sales and has maintained positive results for seven consecutive quarters, despite operating at a loss. High institutional holdings indicate strong investor confidence.
Arcutis Biotherapeutics Hits New 52-Week High of $21.55
Arcutis Biotherapeutics, Inc. has achieved a new 52-week high, reflecting a remarkable performance with a substantial increase over the past year. The company has shown strong financial growth, positive quarterly results, and high institutional ownership, despite being loss-making, indicating confidence in its operational capabilities.
Arcutis Biotherapeutics Hits New 52-Week High of $21.30
Arcutis Biotherapeutics, Inc. has achieved a new 52-week high, reflecting significant growth with a 164.13% increase in net sales and seven consecutive quarters of positive results. Despite operating losses, the company shows resilience with strong cash flow and full institutional backing, highlighting its competitive industry position.
Arcutis Biotherapeutics Hits New 52-Week High of $20.10, Up 162%
Arcutis Biotherapeutics, Inc. achieved a new 52-week high of USD 20.10 on October 1, 2025, reflecting a significant performance increase over the past year. The company reported a 164.13% surge in net sales and has shown consistent growth with seven consecutive quarters of positive results.
Arcutis Biotherapeutics Achieves 101.39% Stock Surge, Establishing It as a Multibagger Performer
Arcutis Biotherapeutics, Inc. has recently undergone a revision in its score, reflecting its impressive performance metrics and strong market position. The company has achieved significant growth in net sales and operating cash flow, showcasing its operational strength and resilience in the Pharmaceuticals & Biotechnology sector.
Arcutis Biotherapeutics Hits New 52-Week High of $19.36
Arcutis Biotherapeutics, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. The company, with a market capitalization of USD 2,080 million, has shown strong growth metrics, including a notable rise in net sales and consistent positive results over seven quarters.
Arcutis Biotherapeutics Hits Day High with Strong 7.29% Intraday Surge
Arcutis Biotherapeutics, Inc. has shown impressive stock performance, with significant gains over various timeframes. The company reported a substantial increase in net sales and has achieved positive results for seven consecutive quarters. High institutional holdings further enhance its market position within the pharmaceuticals and biotechnology sector.
Is Arcutis Biotherapeutics, Inc. technically bullish or bearish?
As of August 12, 2025, Arcutis Biotherapeutics, Inc. shows a bullish trend supported by strong technical indicators, outperforming the S&P 500 in the short term but underperforming over the past 3 and 5 years.
Is Arcutis Biotherapeutics, Inc. overvalued or undervalued?
As of February 28, 2023, Arcutis Biotherapeutics, Inc. is considered a risky investment due to its overvaluation, highlighted by a Price to Book Value of 12.02 and a negative ROCE of -231.44%, despite a year-to-date return of 27.14% that outperformed the S&P 500, which has a long-term return contrast of -32.76% versus the index's 96.61%.
Is Arcutis Biotherapeutics, Inc. overvalued or undervalued?
As of February 28, 2023, Arcutis Biotherapeutics, Inc. is considered overvalued and classified as risky due to poor financial metrics, including a price-to-book ratio of 12.02 and a return on capital employed of -231.44%, despite a 69.61% return over the past year.
Is Arcutis Biotherapeutics, Inc. technically bullish or bearish?
As of May 6, 2025, the trend is mildly bullish with daily moving averages supporting this view, but caution is advised due to mildly bearish signals from the weekly MACD and KST, despite overall positive indicators from Bollinger Bands.
Who are in the management team of Arcutis Biotherapeutics, Inc.?
As of March 2022, the management team of Arcutis Biotherapeutics, Inc. includes Patrick Heron (Independent Chairman), Todd Watanabe (CEO), and directors Terrie Curran, Halley Gilbert, Howard Welgus, Bhaskar Chaudhuri, and Jonathan Silverstein. They oversee the company's strategic direction and operations.
What does Arcutis Biotherapeutics, Inc. do?
Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing treatments for dermatological diseases. As of March 2025, it reported net sales of $66 million and a net loss of $25 million, with a market cap of approximately $1.58 billion.
How big is Arcutis Biotherapeutics, Inc.?
As of Jun 18, Arcutis Biotherapeutics, Inc. has a market capitalization of 1,582.36 million, with recent net sales of 212.83 million and a net profit of -129.72 million. The company reported shareholder's funds of 157.54 million and total assets of 348.89 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
